crizotinib powder
nanjing chemlin biomedical science & technology co, ltd. - crizotinib (unii: 53ah36668s) (crizotinib - unii:53ah36668s) -
crizonix 250mg capsule
crizotinib - capsule - crizotinib inn equavalent to 250mg crizotinib - crizotinib
crizotinib pfizer 200 mg capsules, hard
pfizer laboratories limited, kenya - crizotinib - capsules, hard - 200
crizotinib pfizer 250 mg capsules, hard
pfizer laboratories limited, kenya - crizotinib - capsules, hard - 250
xalkori
pfizer new zealand limited - crizotinib 200mg; ; - capsule - 200 mg - active: crizotinib 200mg excipient: calcium hydrogen phosphate colloidal silicon dioxide gelatin iron oxide red magnesium stearate microcrystalline cellulose sodium starch glycolate tekprint black sw-9008 titanium dioxide - xalkori is indicated for the treatment of patients with anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc). xalkori is indicated for the treatment of patients with ros1-positive advanced non-small cell lung cancer (nsclc).
xalkori
pfizer new zealand limited - crizotinib 250mg; ; - capsule - 250 mg - active: crizotinib 250mg excipient: calcium hydrogen phosphate colloidal silicon dioxide gelatin iron oxide red magnesium stearate microcrystalline cellulose sodium starch glycolate tekprint black sw-9008 titanium dioxide - xalkori is indicated for the treatment of patients with anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc). xalkori is indicated for the treatment of patients with ros1-positive advanced non-small cell lung cancer (nsclc).
xalkori
pfizer europe ma eeig - crizotinib - carcinoma, non-small-cell lung - antineoplastic agents - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to
xalkori capsule
pfizer canada ulc - crizotinib - capsule - 200mg - crizotinib 200mg - antineoplastic agents
xalkori capsule
pfizer canada ulc - crizotinib - capsule - 250mg - crizotinib 250mg - antineoplastic agents
xalkori 200 mg hard capsules
pfizer limited - crizotinib - hard capsules - 200 mg - carcinoma, non-small-cell lung - anti-neoplastic agents, protein kinase inhibitor - indicated for the treatment of adults with previously treated anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc)